NYU Langone Doctors Debunk Brain Health Myths, Highlight 2 FDA-Approved Alzheimer’s Blood Tests
Updated
Updated · NYU Langone Health · Jun 30
NYU Langone Doctors Debunk Brain Health Myths, Highlight 2 FDA-Approved Alzheimer’s Blood Tests
1 articles · Updated · NYU Langone Health · Jun 30
Summary
NYU Langone physicians said brain health depends on basics—sleep, diet, exercise, social connection and mental engagement—while warning that social-media wellness trends and AI advice often distort evidence-based care.
After concussion, doctors now recommend light activity after the first 24 to 48 hours instead of prolonged “cocooning,” and they cautioned that repeated subconcussive hits can cause cumulative harm, especially in youth sports.
Two FDA-approved blood tests for phosphorylated tau can help diagnose Alzheimer’s in symptomatic patients, the experts said, while other biomarkers are advancing ALS studies, neurosurgery monitoring and potential blood-based tumor recurrence detection.
Gut-brain research is widening across neurology, ophthalmology and neurosurgery, with early studies linking microbiome changes to Alzheimer’s risk, ALS progression and macular degeneration; one expert noted 90% of Americans do not get enough fiber.
Doctors also urged caution on unregulated stem-cell and hyperbaric treatments, high-dose supplements and off-label GLP-1 use, citing reports of patient harm and unresolved questions about neurological effects.
After failing Alzheimer's trials, do popular weight-loss drugs pose a hidden risk or hold real promise for brain health?
Experts say basics matter most for brain health, so why is the risky 'biohacking' industry booming?
With AI confidently giving flawed medical advice, are we facing an unprecedented public health crisis?
Revolution in Alzheimer’s Diagnosis: FDA-Approved Blood Tests Offer Early, Affordable Detection in 2025
Overview
In 2025, the FDA approved the first blood tests for Alzheimer's diagnosis, marking a major breakthrough in the field. These tests provide a less invasive and more accessible alternative to traditional methods like PET scans, which are often expensive and complex. With Alzheimer's disease affecting 10% of people over 65 and cases expected to double by 2050, the need for better diagnostic tools is urgent. The introduction of these blood tests is a significant step forward, helping to identify the root cause of cognitive decline in older adults and offering hope for earlier and more accurate detection.